Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome

Lewis H. Kuller, Gregory Grandits, Jerome D. Cohen, James D. Neaton, Ronald Prineas

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


We tested the hypotheses whether nuclear magnetic resonance (NMR) determined lipoprotein particles, insulin and adiponectin, and C-reactive protein (CRP) and white blood cell (WBC) count as markers of inflammation predicted risk of coronary heart disease (CHD) death among 428 men age 35-57 years with metabolic syndrome (MetSyn) in a matched case control study within the multiple risk factor intervention trial. Blood samples collected at entry into the study and stored at -60 °C were obtained from central storage for blood analyte analysis. Two hundred and fourteen men with MetSyn who died of CHD were matched with 214 men with MetSyn who did not die of CHD during 18 years of follow-up. Cases were matched to controls on age, study group, number of factors present in the MetSyn, and presence or absence of a nonfatal CVD event during the trial. Mortality follow-up was determined using the National Death Index. Higher levels of high density lipoprotein particles (HDL-P), especially medium-sized HDL-P [hazard ratio (95% confidence interval) 0.45 (0.25-0.83, P < 0.01), quartile 1 as compared to quartile 4], were associated with lower risk of CHD death. Low density lipoprotein (LDL) particles were not associated with increased risk of CHD. Elevated LDL cholesterol (LDL-C), smoking and WBC count were, but levels of adiponectin, insulin and CRP were not significantly related to CHD death. In multivariate models adjusting for smoking and LDL-C, medium HDL-P and WBC count remained independent predictors of CHD death. Number of HDL particles, especially medium-sized HDL particles and WBC count were independent predictors of CHD death among men with MetSyn.

Original languageEnglish (US)
Pages (from-to)122-128
Number of pages7
Issue number1
StatePublished - Nov 2007

Bibliographical note

Funding Information:
The multiple risk factor intervention trial was conducted under contract with the National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD. The principal investigators and senior staff of the MRFIT clinical, coordinating, and support centers and the NHLBI project office are listed in JAMA 1982; 248(12): 1465–77. This work was supported by NHLBI Grants #R01-HL-43232 and #R01-HL-68140.


  • C-reactive protein
  • Coronary heart disease
  • Lipoproteins
  • Metabolic syndrome
  • White blood cell count


Dive into the research topics of 'Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome'. Together they form a unique fingerprint.

Cite this